

ORIGINAL



Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient: a randomized clinical trial

Christophe Guitton^{1*}, Stephan Ehrmann², Christelle Volteau³, Gwenhael Colin⁴, Adel Maamar⁵, Vanessa Jean-Michel⁶, Pierre-Joachim Mahe⁷, Mickael Landais¹, Noelle Brule⁸, Cedric Bretonnière⁸, Olivier Zambon⁸ and Mickael Vourc'h⁸

© 2019 Springer-Verlag GmbH Germany, part of Springer Nature

Abstract

Purpose: Preoxygenation with high-flow therapy by nasal cannulae (HFNC) is now widespread in the intensive care unit (ICU). However, no large randomized study has assessed its relevance in non-severely hypoxemic patients. In a randomized controlled trial (PROTRACH study), we aimed to evaluate preoxygenation with HFNC vs. standard bag-valve mask oxygenation (SMO) in non-severely hypoxemic patients during rapid sequence intubation (RSI) in the ICU.

Methods: Randomized controlled trial including non-severely hypoxemic patients requiring intubation in the ICU. Patients received preoxygenation by HFNC or SMO during RSI. HFNC was maintained throughout the intubation procedure whereas SMO was removed to perform laryngoscopy. The primary outcome was the lowest pulse oximetry (SpO_2) throughout the intubation procedure. Secondary outcomes included drop in SpO_2 , adverse events related to intubation, and outcome in the ICU.

Results: A total of 192 patients were randomized. In the intent-to-treat analysis, 184 patients (HFNC $n = 95$; SMO $n = 89$), the median [IQR] lowest SpO_2 was 100% [97; 100] for HFNC and 99% [95; 100] for the SMO group ($P = 0.30$). Mild desaturation below 95% was more frequent with SMO (23%) than with HFNC (12%) (RR 0.51, 95% CI 0.26–0.99, $P = 0.045$). There were fewer adverse events in the HFNC group (6%) than in the SMO group (19%) (RR 0.31, 95% CI 0.13–0.76, $P = 0.007$), including fewer severe adverse events, respectively 6 (6%) and 14 (16%) with HFNC and SMO (RR 0.38, 95% CI 0.15–0.95, $P = 0.03$).

Conclusions: Compared with SMO, preoxygenation with HFNC in the ICU did not improve the lowest SpO_2 during intubation in the non-severely hypoxemic patients but led to a reduction in intubation-related adverse events.

Trial registration: Clinical trial Submission: 7 March 2016. Registry name: Benefits of high-flow nasal cannulae oxygen for preoxygenation during intubation in non-severely hypoxemic patients: the PROTRACH study. Clinicaltrials.gov identifier: NCT02700321. Eudra CT: 2015-A00145-44. CPP: 15/13-975 (Comité de protection des personnes de Rennes). URL registry: <https://clinicaltrials.gov/ct2/show/record/NCT02700321>.

*Correspondence: cguitton@ch-lemans.fr

¹ Service de Réanimation Médico Chirurgicale, USC, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037 Le Mans Cedex 9, France
Full author information is available at the end of the article

The data were presented in a preliminary format at the 47th International Congress of the French Reanimation Society in January 2018.

Keywords: Preoxygenation, High-flow oxygen therapy by nasal cannulae, Intubation, Apneic oxygenation, Intensive care unit

Introduction

Endotracheal intubation is a procedure that is performed daily in the intensive care units (ICU). Nevertheless, it remains a life-threatening event and causes more than 25% of severe complications such as oxygen desaturation, hemodynamic instability, and death [1–3], driving intensive research efforts in the field [4–6].

Preoxygenation is a key component of intubation in order to stock up oxygen in functional residual capacity (FRC) volume, representing the main oxygen reservoir during apnea [7]. After the induction of general anesthesia, it extends the duration of apnea until hypoxemia occurs, i.e., oxygen desaturation below a critical pulse oximetry (SpO₂) value [8]. In critically ill patients, several pathological conditions compromise optimal preoxygenation such as high peripheral oxygen uptake, hemodynamic instability, or altered consciousness. In this setting, preoxygenation with the standard bag-valve mask oxygenation (SMO) followed by rapid sequence intubation (RSI) is proposed [9] to reduce the risk of desaturation and aspiration. RSI includes immediate intubation after hypnotic administration without manual face mask ventilation to minimize the time from induction to intubation. SMO is removed during laryngoscopy—meaning that oxygenation of the patient is interrupted. Alternatives such as high-flow therapy by nasal cannulae (HFNC) could prove beneficial. Indeed, considering the encouraging results in patients presenting acute hypoxemic respiratory failure [10], HFNC has been proposed as a preoxygenation device for intubation in the ICU. This device can deliver up to 60 L/min with an inspired fraction of oxygen of up to 100% [11], generate a moderate positive supraglottic end-expiratory pressure, and reduce the patient effort [12]. Contrary to SMO, HFNC makes it possible to hold nasal prongs in place after induction of general anesthesia and during laryngoscopy, to perform apneic oxygenation throughout the intubation procedure [13]. Furthermore, tolerance of HFNC has repeatedly been shown to be excellent whereas SMO can cause discomfort and claustrophobia since the mask is tightly applied to the patient [14]. HFNC is a widespread device in the ICU but there is no large randomized study that has evaluated its benefits as a preoxygenation device for intubation in non-severely hypoxemic patients. We recently reported that this device failed to prevent desaturation during intubation in severely hypoxemic patients [3]. In non-severely hypoxemic patients, a recent

Take-home message

This is the first randomized multicenter study comparing the use of HFNC with SMO for the preoxygenation of non-severely hypoxemic patients in the ICU. In this setting, compared to SMO, preoxygenation with HFNC did not improve the lowest SpO₂ during intubation but led to a reduction in intubation-related adverse events.

before–after study suggested that HFNC could improve preoxygenation and reduce severe hypoxemia during intubation [15].

The main objective was to determine the efficacy of HFNC for preoxygenation compared with SMO as measured by the lowest level of pulse oximetry during RSI recorded through SpO₂. Secondary objectives were to compare intubation procedures, related side effects, and patient outcome in the two groups.

Methods

Study design, setting, and ethical considerations

The PROTRACH study was a multicenter, randomized, controlled, open-label clinical trial. The main objective was to determine the efficacy of HFNC to prevent oxygen desaturation during intubation in the ICU compared with standard of care. Patients were enrolled from April 2016 to June 2017 in seven French ICUs (four medical, two medical-surgical, and one surgical) and followed for 28 days. An independent safety committee oversaw the trial.

Three methods of consent were available; patients were included after written informed consent whenever possible. Most patients were included after the written informed consent of their next-of-kin or following an emergency inclusion procedure. The appropriate ethics committee approved this study protocol in September 2015 (15/13-975).

Participants

Eligible patients were adults (18 years or older), requiring intubation in the ICU, without severe hypoxemia defined as a ratio of arterial partial pressure in oxygen to fraction of inspired oxygen (PaO₂/FiO₂) below 200 within 4 h before inclusion. To determine the PaO₂/FiO₂ ratio on inclusion, the FiO₂ specified by the manufacturer for Venturi mask or corresponding to the oxygen flow for standard nasal prongs [16] was considered.

Exclusion criteria were intubation without rapid sequence induction (i.e., in case of cardiac arrest), fiberoptic intubation, asphyxia requiring immediate

intubation, any nasopharyngeal anatomical obstacle, grade 4 glottis exposure on the Cormack–Lehane scale documented in the medical history, adults subject to legal protection, pregnancy, lack of consent, patients who had already undergone intubation in the ICU (i.e., extubation failure) or who were already participating in an interventional study on preoxygenation.

Randomization

Randomization used fixed blocks of six patients (ratio 1:1) and was stratified by center. The study statistician generated the allocation list. Patients were allocated to one of the two preoxygenation strategies using a secure computer-generated online remote system controlled by the independent research promotion unit at the University Hospital of Nantes which had no role in patient recruitment.

Intervention: preoxygenation and intubation procedure

The study design is described in Supplement 1. Preoxygenation and intubation were performed according to international recommendations in all centers [9]. The intubation team was composed of one junior and one senior.

1. Preoxygenation was started according to the randomization group for a 4-min period [17] in a head-up position. In the intervention group, preoxygenation was performed with HFNC (AIRVO 2™; Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 60 L/min flow of heated and humidified pure oxygen (100% fraction of inspired oxygen, 37 °C). Large or medium nasal cannulae were chosen according to the patient's nostril size to limit air contamination. In the control group, preoxygenation was performed with SMO set at 15 L/min oxygen flow with a disposable self-inflating resuscitator with a reservoir bag manually held in place ensuring air tightness.
2. At the end of preoxygenation, RSI including immediate intubation after administration of the hypnotic drugs was performed in all patients. Drugs and the use of a neuromuscular blocking agent were left to the discretion of the physician.
3. During laryngoscopy and intubation, HFNC was maintained in place throughout the procedure in an attempt to achieve apneic oxygenation. In the control group, SMO was removed in order to perform laryngoscopy.
4. In case of difficult intubation, the stylet was the first alternative device which was proposed [18] if external laryngeal manipulation did not improve glottis vision.

5. At the end of intubation, the correct position of the tracheal tube was confirmed by using capnography [19].

Endpoints

The primary endpoint was the median lowest SpO₂ during intubation, from the beginning of the laryngoscopy until the patient was connected to the mechanical ventilator. To ensure exhaustive data collection, a research nurse and an external observer concurrently collected SpO₂ fluctuations during the intubation.

Secondary endpoints were SpO₂ from the beginning of preoxygenation to the end of intubation focusing on desaturation (below 95%, 90%, 80%); the rate of difficult intubation [20] and the intubation difficulty scale (IDS) score [21]; the need to proceed to face mask ventilation to correct desaturation; adverse events a priori classified as severe (death, cardiac arrest, SpO₂ < 80%, severe hypotension defined by systolic blood pressure < 80 mmHg or vasopressor initiation or 30% dose increment) or moderate (ventricular or supraventricular arrhythmia requiring intervention, esophageal intubation, vomiting with aspiration of gastric content, dental injury); organ failure during the first 5 days (SOFA score); time on the ventilator; length of stay in ICU; occurrence of ventilator-associated pneumonia and mortality rate on day 28 (full study protocol appears in Supplement 2).

Sample size

On the basis of previous studies we hypothesized that HFNC would improve the mean lowest SpO₂ value by 5% (from 88% in the control group to 93% in the HFNC group) with a standard deviation of SpO₂ of 12% [15, 22]. With 80% power, a 5% type I error (two-sided tests), and 5% attrition rate, the required sample size was 192 patients.

Statistical analysis

Baseline characteristics were described as count and percentage for categorical variables and mean and standard deviation or median and interquartiles for quantitative variables when assumption of normality was not met. An intent-to-treat statistical analysis was conducted. Comparisons of primary and secondary outcomes were performed using the Mantel–Haenszel Chi-square tests (or two-tailed Fisher exact tests when appropriate) for qualitative data and the Van Elteren tests for quantitative data to account for stratification factor (center). For qualitative data, relative risk (with adjustment for center effects) and 95% confidence interval were estimated with the Mantel–Haenszel method. Multivariable analysis of SpO₂ < 90%, SpO₂ < 80%, and the occurrence of adverse events were performed using logistic regression. The most clinically

relevant variables (skills of the first operator, difficult intubation, MACOCHA score ≥ 3 , and PaO₂/FiO₂ ratio at baseline) or associated with the randomization group (P values < 0.20) in univariate analysis (age and NYHA class) were introduced simultaneously into the models. Odds ratios and their 95% confidence intervals (CI) were estimated. All tests were two-tailed. P values of less than 0.05 were considered significant. No data was missing for the primary outcome. For secondary outcomes, missing data were clearly stated in the tables (see also Supplement 3), and no method of imputation was used. SAS software version 9.4 (SAS Institute Inc.) was used.

Results

Patients

In the seven participating ICUs, 192 patients were randomized in the study between April 2016 and June 2017. Three patients withdrew their consent, two patients were discovered to be under guardianship protection, and three patients improved before the start of the study and were therefore not intubated. We considered 184 patients (95 in HFNC and 89 in SMO) in the intent-to-treat (ITT) and 183 patients in the per-protocol (PP) analyses (Fig. 1). Per-protocol analysis excluded the only patient with protocol deviation in the HFNC group who did not receive preoxygenation with HFNC because no device was available. This patient did not present any complication during intubation.

At baseline, patients were mainly intubated for a medical condition with a median [interquartile range, IQR] simplified acute physiology score 2 (SAPS II) of

45 [35; 60] in HFNC and 41 [32; 57] in SMO; median [IQR] PaO₂/FiO₂ was 318 mmHg [242; 396] in HFNC and 375 mmHg [276; 446] in SMO. In the two groups, intubation was mainly performed for neurologic reasons in comatose patients: 68% in HFNC and 75% in SMO (Table 1). In order to prevent hypotension, fluid loading was performed before anesthesia induction in 41 (43%) patients in HFNC vs. 37 (42%) in SMO. Airways, operators, and technical aspects of intubation are described in Table 2. Mean (standard deviation, SD) MACOCHA score to predict difficult intubation was 2.0 (1.6) in HFNC and 2.2 (2.0) in SMO [23]. There was no between-group difference in doses or nature of hypnotics (see Supplement 3). All intubations were performed with two operators including a senior and the first operators were mainly (84%) juniors. In the HFNC group, cannula sizes were large for 45% and medium for 55%. No patient was lost to follow-up (see Supplement 3).

Primary outcome: lowest SpO₂ during the intubation procedure

In the intent-to-treat (ITT) analysis (Table 3, Fig. 2), there was no significant difference between the median [IQR] lowest SpO₂ during intubation in the HFNC group compared with the SMO group, 100% [97; 100] versus 99% [95; 100] respectively, ($P=0.30$). In the per-protocol (PP) analysis (attrition rate 1%), the lack of difference persisted ($P=0.26$). Although only non-severely hypoxemic patients were included, the lowest SpO₂ during intubation ranged from 69% to 100% in HFNC and from 43% to 100% in SMO.




Fig. 1 Study flowchart. HFNC high-flow nasal cannulae, SMO standard bag-valve mask oxygenation

Table 1 Baseline characteristics of the intent-to-treat population

	High-flow nasal cannulae <i>n</i> = 95	Standard bag-valve mask oxygenation <i>n</i> = 89
Sex ratio M/F	65/30	62/27
Age, median [IQR], year	60 [49; 72]	61 [41; 68]
BMI, mean (SD) ^a	27.0 (6.6)	25.9 (5.5)
Medical patients, <i>n</i> (%)	90 (95)	87 (98)
SAPS II score, median [IQR]	45 [35; 60]	41 [32; 57]
Comorbidities		
Chronic heart failure (NYHA III or IV), <i>n</i> (%)	0	3 (3)
Chronic respiratory failure, <i>n</i> (%)	8 (8)	10 (11)
Obstructive sleep apnea syndrome, <i>n</i> (%)	1 (1)	5 (6)
COPD, <i>n</i> (%) ^b	8 (9)	8 (9)
Past upper airway tract cancer, <i>n</i> (%)	1 (1)	0
Diabetes, <i>n</i> (%)	11 (12)	8 (9)
Vasopressor support, <i>n</i> (%)	11 (12)	12 (14)
Glasgow coma score, mean (SD)	8 [5; 14]	9 [6; 14]
McCabe scale 2 or 3, <i>n</i> (%) ^c	13 (14)	15 (17)
Functional status (class C or D KNAUS), <i>n</i> (%) ^d	8 (8)	14 (16)
Main indications for intubation, <i>n</i> (%)		
Acute respiratory failure	14 (15)	7 (9)
Comatose patients	65 (68)	67 (75)
Hemodynamic dysfunction	7 (7)	4 (4)
Other	9 (10)	11 (12)
Advanced oxygenation support before inclusion, <i>n</i> (%)		
Non-invasive ventilation	6 (6)	8 (9)
HFNC	3 (3)	2 (2)
Arterial blood gas oxygenation before intubation		
PaO ₂ /FiO ₂ , median [IQR], mmHg	318 [242; 396]	375 [276; 446]
PaCO ₂ , mean (SD), mmHg	36 [30; 46]	37 [29.6; 47]
SpO ₂ , median [IQR], %	97 [95; 99]	98 [96; 100]

BMI body mass index, SAPSII simplified acute physiological score (used to assess the severity of illness; range 0–194, with higher scores indicating higher risk of death), COPD chronic obstructive pulmonary disease, HFNC high-flow therapy by nasal cannulae

^a Calculated as weight in kilograms divided by height in square meters

^b COPD was considered if obstructive syndrome had been documented on functional explorations

^c McCabe classification: cat 1, nonfatal disease; cat 2, ultimately fatal disease (within 4 years); cat 3, rapidly fatal disease

^d KNAUS chronic health status: class A, normal health status; class B, moderate activity limitation; class C, severe activity limitation due to chronic disease; class D, bedridden patient

Secondary outcomes

All of the patients were successfully intubated and only one operator removed HFNC for laryngoscopic vision obstruction. At the end of the preoxygenation period, median [IQR] SpO₂ was 100% [100; 100], ($P=0.66$) in both groups (Table 3). During preoxygenation, jaw-thrust maneuver was performed in 13% of the patients in HFNC and in 33% in SMO (relative risk 0.38, 95% CI 0.21–0.71, $P=0.0009$). The median [IQR, min–max] length of intubation (namely, apnea duration) was higher in HFNC (1 [0.5; 1.9, 0–23]) vs. in SMO (0.8 [0.5; 1.4, 0–18] min, $P=0.04$). Eleven patients (12%) in HFNC vs. 20 (23%) in

SMO experienced an SpO₂ drop below 95% (relative risk 0.51, 95% CI 0.26–0.99, $P=0.045$). Six patients (6%) in the HFNC group vs. 12 (14%) in the SMO group experienced an SpO₂ < 90% ($P=0.10$). Two patients (2%) in the HFNC group vs. 7 (8%) in the SMO group experienced a severe SpO₂ < 80% ($P=0.06$). Overall, during intubation, 6 patients (6%) in the HFNC group vs. 17 patients (19%) in the SMO group (relative risk 0.31, 95% CI 0.13–0.76, $P=0.007$) presented at least one intubation-related complication. Severe complications including SpO₂ < 80%, severe hypotension, and cardiac arrest occurred in 6% of the patients in HFNC vs. 16% in SMO (relative risk

Table 2 Airway, preoxygenation, and intubation settings at baseline

	High-flow nasal cannulae <i>n</i> = 95	Standard bag-valve mask oxygenation <i>n</i> = 89
Airway description		
At least two difficult mask ventilation criteria, <i>n</i> (%) ^a	46 (48)	39 (44)
Medical story of difficult intubation, <i>n</i> (%)	4/59 (7)	0/54 (0)
Mouth opening less than 3 cm, <i>n/n</i> tot ^b (%)	8/71 (11)	11/78 (15)
Limitation of cervical mobility $\leq 35^\circ$, <i>n/n</i> tot ^b (%)	5/61 (8)	2/67 (3)
Mallampati III or IV, <i>n/n</i> tot ^b (%)	10/34 (29)	14/42 (33)
Thyroid bone to chin distance < 65 mm, <i>n/n</i> tot ^b (%)	7/52 (14)	10/61 (16)
MACOCHA score, mean (SD) ^c	2.0 (1.6)	2.2 (2.0)
Urgency of intubation, <i>n</i> (%)^d		
High emergency	16 (17)	16 (18)
Relative emergency	66 (69)	59 (66)
Deferred emergency	13 (14)	14 (16)
Preoxygenation, <i>n</i> (%)		
4 min or more	90 (97)	81 (91)
Leaks around the device ^e	5 (5)	11 (12)
Preventive fluid loading before induction	41 (43)	37 (42)
Intubation		
First operator, junior, <i>n</i> (%) ^f	80 (84)	75 (84)
Drugs for rapid sequence induction		
Hypnotic agent, <i>n</i> (%)		
Propofol	17 (18)	17 (19)
Etomidate	62 (65)	57 (65)
Ketamine	12 (13)	11 (12)
Other	3 (3)	4 (4)
None	1 (1)	0
Neuromuscular blocking agent, <i>n</i> (%) ^g		
Succinylcholine	64 (67)	57 (65)
Rocuronium	23 (25)	22 (25)
Other	3 (3)	4 (5)
None	5 (5)	6 (7)

BMI body mass index, *SAPSII* simplified acute physiological score: used to assess the severity of illness: range 0–194, with higher scores indicating higher risk of death, *COPD* chronic obstructive pulmonary disease, *HFNC* high-flow therapy by nasal cannulae

^a Calculated as weight in kilograms divided by height in square meters

^b *COPD* was considered if obstructive syndrome had been documented on functional explorations

^c McCabe classification: cat 1, nonfatal disease; cat 2, ultimately fatal disease (within 4 years); cat 3, rapidly fatal disease

^d *KNAUS* chronic health status: class A, normal health status; class B, moderate activity limitation; class C, severe activity limitation due to chronic disease; class D, bedridden patient

^e Leaks around the device were defined as leaks around the face mask during inspiration or expiration (SMO) or leaks by the mouth when breathing with the mouth open (HFNC)

^f Residents were considered as junior operators. Doctors of medicine were considered as seniors

^g Some patients received several drugs

0.38, 95% CI 0.15–0.95, $P=0.03$). No patient in the HFNC group presented moderate complications vs. 7% in the SMO group, $P=0.01$ (Table 3 and see Supplement 3). Multivariable analysis showed that HFNC was associated with less desaturation < 90%, less intubation-related complications, and a trend to reduce oxygen

desaturation < 80% ($P=0.058$) (see Table 4 and Supplement 3). When the complications during intubation and the following hour were pooled, the results followed the same trends (see Supplement 3). The description of the drugs used for RSI and the type of adverse events are described in Supplement 3.

Table 3 Primary and secondary outcomes

	High-flow nasal cannulae <i>n</i> = 95	Standard bag-valve mask oxygenation <i>n</i> = 89	<i>P</i>	Relative risk or difference (95% CI)
Primary outcome				
Lowest SpO ₂ , median [IQR], %, ITT analysis	100 [97; 100]	99 [95; 100]	0.30	
Lowest SpO ₂ , min–max, %	69–100	43–100		
Secondary outcomes				
Preoxygenation				
SpO ₂ at the beginning, median [IQR], %	98 [96; 100]	98 [97; 100]	0.75	
SpO ₂ at the end, median [IQR], %	100 [100; 100]	100 [100; 100]	0.66	
Jaw-thrust maneuver, <i>n</i> (%) ^a	12/94 (13)	29 (33)	0.0009	0.38 (0.21–0.71)
Failure to reach SpO ₂ 90%, <i>n</i> (%)	2 (2)	0	0.19	
Intubation				
Two or more operators, <i>n</i> (%)	27 (28)	14 (16)	0.06	1.74 (0.97–3.12)
Length, median [IQR], mins ^b	1 [0.5; 1.9]	0.8 [0.5; 1.4]	0.04	
Successful intubation, <i>n</i> (%)	95 (100)	89 (100)	0.9	
Difficult intubation, <i>n</i> (%) ^c	9 (10)	1 (1)	0.01	8.58 (1.04–70.82)
IDS score, median [IQR] ^d	3 [2; 5]	3 [2; 4]	0.10	
Mask ventilation for SpO ₂ < 90%, <i>n</i> (%)	1 (1)	5 (6)	0.08	0.16 (0.02–1.62)
SpO ₂ < 95%, <i>n</i> (%)	11 (12)	20 (23)	0.045	0.51 (0.26–0.99)
SpO ₂ < 90%, <i>n</i> (%)	6 (6)	12 (14)	0.1	1.09 (0.98–1.20)
Intubation-related adverse events				
At least one complication, <i>n</i> (%)	6 (6)	17 (19)	0.007	0.31 (0.13–0.76)
At least one severe complication, <i>n</i> (%) ^f	6 (6)	14 (16)	0.03	0.38 (0.15–0.95)
SpO ₂ < 80%	2 (2)	7 (8)	0.06	0.26 (0.05–1.20)
Severe hypotension ^e	4 (4)	8 (9)	0.18	0.45 (0.13–1.48)
Cardiac arrest	1 (1)	0	0.36	–
At least one moderate complication, <i>n</i> (%) ^f	0	6 (7)	0.01	–
Esophageal intubation	0	5 (6)	0.02	–
Aspiration	0	2 (2)	0.15	–
Morbidity in the ICU after intubation				
Time on ventilator, median [IQR], days	3 [2; 6]	3 [2; 7]	0.80	
Ventilator-associated pneumonia, <i>n</i> (%)	8 (8)	10 (11)	0.55	0.77 (0.32–1.84)
SOFA score from day 1–5, median [IQR]	5 [3; 9]	6 [4; 10]	0.26	
Length of stay in ICU, median [IQR], days	5 [3; 12]	6 [3; 11]	0.89	
Death, <i>n</i> (%)	25 (26)	23 (26)	0.90	1.03 (0.65–1.65)
Mortality at day 28, <i>n</i> (%)	26 (27)	24 (27)	0.93	0.99 (0.90–1.24)

Bold values represent *P* < 0.05

SOFA sequential organ failure assessment used to assess the degree of dysfunction of five organ systems: respiratory, cardiovascular, renal, neurologic, hepatic. Each subscore ranged from 0 (healthy) to 4 (maximum severity); the overall score ranged from 0 to 20 [33]

In the HFNC group, one patient experienced a cardiac arrest secondary to deep desaturation during intubation because of difficult airway control (body mass index > 45)

ICU intensive care unit, SpO₂ arterial saturation measured by pulse oximetry, PaO₂ partial pressure of oxygen in arterial blood

^a Defined as the need to perform subluxation to ensure airway permeability for spontaneous breathing during preoxygenation


^b The length of intubation corresponds to the length of apnea. The external observer started the chronometer when the nurse injected hypnotics and stopped when the patient was connected to a ventilator

^c Difficult intubation was defined as intubation duration longer than 10 min and/or three or more laryngoscopy attempts or use of an alternative device [20]

^d IDS score was calculated after intubation to evaluate the difficulty of the intubation. IDS < 5 means slightly difficult intubation. IDS > 5 means moderate to major difficult intubation [21]

^e Severe hypotension was defined as systolic blood pressure < 80 mmHg or vasopressor introduction or 30% dose increment

^f Some patients experienced several distinct complications



ITT N = 184	Median [IQR]	100 [97;100]	99 [95;100]	P = 0.30
	Mean (SD)	97 (5)	95 (12)	
PP N = 183	Median [IQR]	100 [97;100]	99 [95;100]	P = 0.26
	Mean (SD)	97 (5)	95 (12)	

Fig. 2 Primary outcome: lowest SpO₂ during the intubation procedure. HFNC high-flow nasal cannulae, SMO standard bag-valve mask oxygenation, ITT intent-to-treat analysis, PP per-protocol analysis, SD standard deviation, IQR interquartile range, SpO₂ arterial oxygen saturation measured by pulse oximetry

Patients in the HFNC and SMO groups had comparable median [IQR] durations of mechanical ventilation, respectively 3 [2; 6] vs. 3 [2; 7] days, $P=0.80$. There was also no difference in SOFA score during the first 5 days after randomization and the length of stay in the ICU ($P=0.89$). The mortality rate on day 28 was 27% in both groups, $P=0.93$.

Discussion

During intubation in non-severely hypoxemic critically ill patients, HFNC as a preoxygenation and apneic oxygenation device did not increase the median lowest SpO₂ compared with SMO. However, HFNC significantly reduced intubation-related complications by threefold including severe complications. The latter result is a

Table 4 Multivariable analysis for desaturation <90% or complications during intubation

N=175 ^a	Desaturation <90%			Severe and moderate complications		
	OR	CI	P	OR	CI	P
First operator, senior	0.49	0.09–2.56	0.39	2.07	0.69–6.22	0.20
Age	1.02	0.99–1.06	0.22	1.01	0.98–1.04	0.48
HFNC (vs. SMO)	0.21	0.06–0.72	0.01	0.26	0.08–0.77	0.02
Difficult intubation, no	0.08	0.01–0.48	0.005	2.14	0.73–6.21	0.16
MACOCHA score ≥ 3, yes	0.87	0.24–3.21	0.84	1.00	1.00–1.01	0.37
NYHA III or IV, yes	0.32	0.02–4.78	0.40	0.22	0.04–1.32	0.10
PaO ₂ /FiO ₂ at inclusion	0.99	0.99–1.00	0.06	0.93	0.07–12.45	0.10

Bold values represent $P < 0.05$

In order to account for potential confounders, multivariable analysis on secondary outcomes were performed. Clinically relevant data (skill of the first operator, difficult intubation, MACOCHA score 3, and PaO₂/FiO₂ ratio at baseline) or associated with the randomization group (age and NYHA class) were included in the multivariable analysis. Log linearity was checked for each parameter and adequacy of the model was verified by Hosmer and Lemeshow goodness-of-fit. Odds ratio (OR) < 1 represents protective factors

^a The multivariable analyses were performed in 175 patients because some data were missing for 9 patients

major finding considering the high rate of complications observed in the present study, i.e., occurring in more than 10% of patients, despite inclusion of non-severely hypoxemic patients. Considering that only one operator removed HFNC during intubation, holding the nasal prongs in place during intubation did not appear to obstruct vision or interfere with intubation.

Our team has already reported that preoxygenation in severely hypoxemic patients with HFNC compared with SMO did not improve median lowest SpO₂ during intubation [3]. To our knowledge, the present study is the first large multicenter randomized clinical trial assessing HFNC preoxygenation before intubation in non-severely hypoxemic critically ill patients. The only publication available in this setting was the study by Miguel-Montanes et al. [15]. Their study reported an improvement in the median lowest SpO₂ during intubation and a reduction in severe oxygen desaturations when using HFNC compared with face mask for preoxygenation. Although it included patients with baseline characteristics close to ours, the before–after and single-center design may have overestimated the treatment effect, limiting the generalization of the results and their reproducibility in multicenter studies. In the PROTRACH study, these trends were not confirmed, but HFNC appeared as a protective factor for desaturation <90% in multivariable analysis (see Table 4). In line with previous studies [2, 6], and similar to hypoxemic patients [3], our results highlighted that non-severely hypoxemic patients experience numerous life-threatening adverse events during intubation including deep desaturation with minimum SpO₂ of 69% in HFNC vs. 43% in SMO.

Each complication related to preoxygenation or intubation was immediately declared by the investigators

and reviewed by the safety board, ensuring high reporting accuracy. Patients undergoing HFNC preoxygenation experienced fewer adverse events, including fewer severe (mainly SpO₂ < 80%) and moderate complications. Several theoretical advantages of HFNC could explain these results. HFNC has already been reported to improve FRC, one of the main determinants of the duration of apnea without desaturation. Reducing the risk of desaturation, HFNC could in turn reduce complications such as hypotension related to hypoxemia [24]. Compared with SMO requiring two-handed thenar eminence grip to perform jaw-thrust maneuver and ensure airtightness, HFNC is a “hands-free” preoxygenation device that could help operators to be more confident and avoid scrambled intubation. Nevertheless, this aspect was not specifically assessed in the study. The reduction of desaturation <95% in the HFNC group despite longer and more difficult intubation could also be recognized as a marker of apneic oxygenation even if this remains controversial [25]. Preoxygenation has to be differentiated from apneic oxygenation [26]. As exhaled fraction of oxygen (EtO₂) was not assessed, the reduction of desaturation in HFNC should not be interpreted as increased oxygen reserves at the end of the preoxygenation compared with SMO. However, the administration of oxygen during the apnea period with HFNC could explain the lower rate of respiratory adverse events. These results are concordant with the OPTINIV study [13]. This study showed that in severe hypoxemic patients the preoxygenation with non-invasive ventilation (NIV, namely the gold standard device in this setting [22, 27]) combined with HFNC increased the lowest saturation during intubation compared to NIV alone. Overall, a comprehensive improvement of the intubation process including preoxygenation

optimization, better ergonomics for the operator, and possible apneic oxygenation to offset oxygen uptake during intubation could account for these results. The technical aspect of preoxygenation with SMO can probably explain the high rate of jaw-thrust maneuver in this group.

The rate of intubation-related complications was higher in the SMO group. Strikingly, in the HFNC group difficult intubation and intubation for acute respiratory failure were more frequent, and median PaO₂/FiO₂ was lower ($P=0.009$) and should have led to an increase in the number of desaturation and adverse events in this group. Thus, in order to account for potential baseline imbalance, a multivariable analysis was performed and found that HFNC preoxygenation was associated with a fivefold decrease in oxygen desaturation below 90% and a fourfold decrease in intubation-related complications. Nevertheless, given the small number of intubation-related adverse events, we need to be cautious before generalizing these results.

The study includes unselected patients regardless of their admission diagnosis, in medical and surgical settings from academic and non-academic hospitals, reflecting daily practice in the ICUs and enhancing external validity. In this setting, albeit negative in terms of the primary outcome, the study provided several findings suggesting that HFNC could secure intubation by reducing complications including desaturations. Although this study enrolled ICU patients, these results could be applied to all intubations in the emergency department in non-severely hypoxemic patients considering that HFNC is now a widespread oxygenation device.

This trial has several limitations. An unblinded preoxygenation device may have interfered with our findings. Although feasible [13], blinding may have been very difficult to maintain in a large sample and multicenter trial. The choice of the primary outcome can be discussed. Considering the Miguel-Montanes et al. results, we decided to assess minimal SpO₂ instead of severe desaturation below 80%, a common criteria which, however, is infrequent in the non-severely hypoxemic patient. In the same way, whether a 5% difference of SpO₂ is a clinically relevant endpoint may be questionable. However, such a difference can lead to a decision of bag-valve mask ventilation or can initiate a fast and deep hypoxemia given the sigmoidal relationship between the affinity of hemoglobin for oxygen and the PaO₂. In this study, the 5% difference was not met. SpO₂ is not the most relevant parameter to assess oxygenation [28], but systematic arterial catheterization before intubation to measure arterial oxygen saturation or partial oxygen pressure could not be ethically defended. Similarly, EtO₂ could have been a relevant way to assess the quality of preoxygenation, in particular

to check that the preoxygenation was well performed in the SMO group, with a mask correctly applied to avoid leaks. It is an indicator of FRC oxygen saturation and when EtO₂ >90% is achieved, preoxygenation can be claimed to be effective [29]. Nevertheless, in a non-occlusive device such as HFNC, measurement of EtO₂ was difficult to achieve [30]. In the same way, the precise level of post-apnea end-tidal carbon dioxide (EtCO₂) was not recorded and could have provided relevant information [31]. However, we made the pragmatic choice to evaluate SpO₂, the only worldwide, non-invasive, and ready-to-use device informing the attending physician on apnea tolerance during intubation. Given the limitations of SpO₂ measurement, a research nurse was specifically dedicated to monitor SpO₂ throughout the procedure to improve data collection. Finally, NIV was not selected as the active comparator. Although it was found to improve preoxygenation in obese patients in the operating room [32], and in severe hypoxemic patients in ICU [22, 33], no data is available in non-severely hypoxemic patients in the ICU.

Conclusion

Compared with SMO, preoxygenation with HFNC provided similar lowest SpO₂ during intubation in the ICU. However, HFNC was associated with enhanced safety of the procedure. These secondary results need to be confirmed and could be in favor of performing apneic oxygenation following preoxygenation in non-severely hypoxemic ICU patients.

Electronic supplementary material

The online version of this article (<https://doi.org/10.1007/s00134-019-05529-w>) contains supplementary material, which is available to authorized users.

Author details

¹ Service de Réanimation Médico Chirurgicale, USC, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037 Le Mans Cedex 9, France. ² Médecine Intensive Réanimation, INSERM CIC 1415, Centre Hospitalier Universitaire de Tours, Centre d'Etude des Pathologies Respiratoires INSERM U1100, Tours University, Tours, France. ³ Plateforme de Méthodologie et de Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France. ⁴ Médecine Intensive Réanimation, Centre Hospitalier de La Roche sur Yon, La Roche-Sur-Yon, France. ⁵ Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France. ⁶ Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France. ⁷ Service d'Anesthésie-Réanimation Chirurgicale, Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France. ⁸ Médecine Intensive Réanimation, Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Acknowledgements

Collaborators and additional contributions: We are grateful to all medical staff, nurses, and research staff at the seven sites for inclusion and data collection. We thank Caroline Postnikoff (University Hospital of Nantes) for administrative and logistic support and Marion Rigot (University Hospital of Nantes) for creating the electronic Case Report Form and Dr. Anne Chiffolleau, MD for safety monitoring (University Hospital of Nantes). The safety board was composed of Dr. Christophe Girault (University Hospital of Rouen), Prof. Gilles Capellier

(University Hospital of Besancon) and Prof. Antoine Roch (University Hospital of Marseille).

Data sharing statements: Deidentified data collected for the study, including individual participant data and a data dictionary defining each field, in the set will be made available to others. Study protocol, statistical analysis plan, informed consent form, and record of the primary outcome will be made available on reasonable request by addressing an email to the corresponding author in the 5 years following publication with investigator support.

Author contributions

CG and MV had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: MV, CG, OZ, CB, and SE. Data acquisition: all of the authors participated in data collection and acquisition. Data analysis and interpretation: CG, MV, CB, SE, and CV. Drafting of the manuscript: CG, MV, CB, OZ, and SE. Critical revision of the manuscript for important intellectual content: All of the authors. Statistical analysis: CV. Funding obtained: CG and OZ. Administrative, technical, or material support: All of the clinician authors. Study supervision: MV and CG.

Financial and material support for the research and the grant support, funding source, and provision of equipment and supplies

This study was supported by the French Ministry of Health (Interregional French Clinical Hospital Research Program Grant; PHRCi 2014—API12/N/077) in addition to a grant for research & innovation missions allocated to the University Hospital of Nantes and by Fisher & Paykel Healthcare. The University Hospital of Nantes was the sponsor of the study. The equipment was loaned by Fisher & Paykel Healthcare whereas nasal cannulae were bought with the funds of PHRCi.

Fisher & Paykel participation was inferior to 5% of the total budget (3500 €). Fisher & Paykel did not participate in the design and conduct of the study, nor in data collection, management, analysis and interpretation of the data, nor in the preparation, review, approval, and decision to submit the manuscript for publication.

Compliance with ethical standards

Conflicts of interest

Christelle Volteau, Colin Gwenaël, Adel Maamar, Vanessa Jean-Michel, Pierre Joachim Mahe, Mickaël Landais, Noëlle Brule, Cedric Bretonnière, Olivier Zambon, and Christophe Guitton declare no conflict of interest. Stephan Ehrmann declares receiving consultancy fees from Aerogen Ltd, La Diffusion Technique Française, and Baxter healthcare and unrestricted research support from Fisher and Paykel, Aerogen Ltd, and Hamilton Medical. Mickael Yourc'h declares personal fees from MSD, Pfizer, Baxter, Grants from Fisher Paykel, outside the submitted work.

Ethical approval

The appropriate ethics committee approved this study protocol in September 11 2015 (15/13-975).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 November 2018 Accepted: 11 January 2019

Published online: 21 January 2019

References

- Jaber S, Amraoui J, Lefrant J-Y et al (2006) Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit: a prospective, multiple-center study. *Crit Care Med* 34:2355–2361. <https://doi.org/10.1097/01.CCM.0000233879.58720.87>
- De Jong A, Rolle A, Molinari N et al (2018) Cardiac arrest and mortality related to intubation procedure in critically ill adult patients: a multi-center cohort study. *Crit Care Med* 46:532–539. <https://doi.org/10.1097/CCM.0000000000002925>
- Yourc'h M, Asfar P, Volteau C et al (2015) High-flow nasal cannula oxygen during endotracheal intubation in hypoxemic patients: a randomized controlled clinical trial. *Intensive Care Med*. <https://doi.org/10.1007/s00134-015-3796-z>
- Jaber S, Jung B, Corne P et al (2010) An intervention to decrease complications related to endotracheal intubation in the intensive care unit: a prospective, multiple-center study. *Intensive Care Med* 36:248–255. <https://doi.org/10.1007/s00134-009-1717-8>
- De Jong A, Clavieras N, Conseil M et al (2013) Implementation of a combo videolaryngoscope for intubation in critically ill patients: a before-after comparative study. *Intensive Care Med* 39:2144–2152. <https://doi.org/10.1007/s00134-013-3099-1>
- Lascarrou J-B, Boisrame-Helms J, Bailly A et al (2017) Video laryngoscopy vs. direct laryngoscopy on successful first-pass orotracheal intubation among ICU patients: a randomized clinical trial. *JAMA* 317:483–493. <https://doi.org/10.1001/jama.2016.20603>
- Russotto V, Cortegiani A, Raineri SM et al (2017) Respiratory support techniques to avoid desaturation in critically ill patients requiring endotracheal intubation: a systematic review and meta-analysis. *J Crit Care* 41:98–106. <https://doi.org/10.1016/j.jcrc.2017.05.003>
- Benumof JL (1999) Preoxygenation: best method for both efficacy and efficiency. *Anesthesiology* 91:603–605
- Higgs A, McGrath BA, Goddard C et al (2018) Guidelines for the management of tracheal intubation in critically ill adults. *Br J Anaesth* 120:323–352. <https://doi.org/10.1016/j.bja.2017.10.021>
- Frat J-P, Thille AW, Mercat A et al (2015) High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 372:2185–2196. <https://doi.org/10.1056/NEJMoa1503326>
- Roca O, Riera J, Torres F, Masclans JR (2010) High-flow oxygen therapy in acute respiratory failure. *Respir Care* 55:408–413
- Vargas F, Saint-Leger M, Boyer A et al (2015) Physiologic effects of high-flow nasal cannula oxygen in critically care subjects. *Respir Care* 60:1369–1376. <https://doi.org/10.4187/respcare.03814>
- Jaber S, Monnin M, Girard M et al (2016) Apnoeic oxygenation via high-flow nasal cannula oxygen combined with non-invasive ventilation preoxygenation for intubation in hypoxaemic patients in the intensive care unit: the single-centre, blinded, randomised controlled OPTINIV trial. *Intensive Care Med* 42:1877–1887. <https://doi.org/10.1007/s00134-016-4588-9>
- Badiger S, John M, Fearnley RA, Ahmad I (2015) Optimizing oxygenation and intubation conditions during awake fibre-optic intubation using a high-flow nasal oxygen-delivery system. *Br J Anaesth* 115:629–632. <https://doi.org/10.1093/bja/aeu262>
- Miguel-Montanes R, Hajage D, Messika J et al (2015) Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. *Crit Care Med* 43:574–583. <https://doi.org/10.1097/CCM.00000000000000743>
- Ward JJ (2012) High-flow oxygen administration by nasal cannula for adult and perinatal patients. *Respir Care* 58:98–122. <https://doi.org/10.4187/respcare.01941>
- Mort TC (2005) Preoxygenation in critically ill patients requiring emergency tracheal intubation. *Crit Care Med* 33:2672–2675
- Frerik C, Mitchell VS, McNarry AF et al (2015) Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. *Br J Anaesth* 115:827–848. <https://doi.org/10.1093/bja/aeu371>
- Grmec S (2002) Comparison of three different methods to confirm tracheal tube placement in emergency intubation. *Intensive Care Med* 28:701–704. <https://doi.org/10.1007/s00134-002-1290-x>
- American Society of Anesthesiologists Task Force on Management of the Difficult Airway (2003) Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. *Anesthesiology* 98:1269–1277
- Adnet F, Borron SW, Racine SX et al (1997) The intubation difficulty scale (IDS): proposal and evaluation of a new score characterizing the complexity of endotracheal intubation. *Anesthesiology* 87:1290–1297
- Baillard C, Fosse J-P, Sebbane M et al (2006) Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. *Am J Respir Crit Care Med* 174:171–177. <https://doi.org/10.1164/rccm.200509-1507OC>

23. De Jong A, Molinari N, Terzi N et al (2013) Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACOCHA score in a multicenter cohort study. *Am J Respir Crit Care Med* 187:832–839. <https://doi.org/10.1164/rccm.201210-1851OC>
24. Langeron O, Bourgain J-L, Francon D et al (2017) Difficult intubation and extubation in adult anaesthesia. *Anesth Réanim* 3:552–571. <https://doi.org/10.1016/j.anrea.2017.09.003>
25. Semler MW, Janz DR, Lentz RJ et al (2015) Randomized trial of apneic oxygenation during endotracheal intubation of the critically ill. *Am J Respir Critical Care Med*. <https://doi.org/10.1164/rccm.201507-1294oc>
26. Papazian L, Corley A, Hess D et al (2016) Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. *Intensive Care Med*. <https://doi.org/10.1007/s00134-016-4277-8>
27. Quintard H, l'Her E, Pottecher J et al (2017) Intubation and extubation of the ICU patient. *Anaesth Crit Care Pain Med* 36:327–341. <https://doi.org/10.1016/j.accpm.2017.09.001>
28. Perkins GD, McAuley DF, Giles S et al (2003) Do changes in pulse oximeter oxygen saturation predict equivalent changes in arterial oxygen saturation? *Crit Care* 7:R67–R67. <https://doi.org/10.1186/cc2339>
29. Pillai A, Daga V, Lewis J et al (2016) High-flow humidified nasal oxygenation vs. standard face mask oxygenation. *Anaesthesia* 71:1280–1283. <https://doi.org/10.1111/anae.13607>
30. Ang KS, Green A, Ramaswamy KK, Frerk C (2017) Preoxygenation using the Optiflow™ system. *Br J Anaesth* 118:463–464. <https://doi.org/10.1093/bja/aex016>
31. Patel A, Nouraei SAR (2015) Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE): a physiological method of increasing apnoea time in patients with difficult airways. *Anaesthesia* 70:323–329. <https://doi.org/10.1111/anae.12923>
32. Futier E, Constantin J-M, Pelosi P et al (2011) Noninvasive ventilation and alveolar recruitment maneuver improve respiratory function during and after intubation of morbidly obese patients: a randomized controlled study. *Anesthesiology* 114:1354–1363. <https://doi.org/10.1097/ALN.0b013e31821811ba>
33. Baillard C, Prat G, Jung B et al (2018) Effect of preoxygenation using non-invasive ventilation before intubation on subsequent organ failures in hypoxaemic patients: a randomised clinical trial. *Br J Anaesth* 120:361–367. <https://doi.org/10.1016/j.bja.2017.11.067>